NCT02714595已完成3 期
A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Shionogi1 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2016年9月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 152
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis
研究概览
简要总结
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
详细描述
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients with either hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), healthcare-associated pneumonia (HCAP), complicated urinary tract infection (cUTI), or bloodstream infections (BSI)/sepsis caused by carbapenem-resistant Gram-negative pathogens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with clinically documented infection (HAP/VAP/HCAP, cUTI, or BSI/sepsis) caused by a Gram-negative pathogen with evidence of carbapenem resistance
- •Patients who have been treated previously with an empiric antibiotic regiment and failed treatment, both clinically and microbiologically, are eligible for the study, if they have an identified carbapenem-resistant Gram-negative pathogen which has either been shown to be nonsusceptible in vitro to each of the antibiotic(s) of the empiric antibiotic regimen or been grown from a culture performed after at least 2 days of the empiric antibiotic regimen
- •Patient is male (no contraception required) or female and meets one of the following criteria:
- •Surgically sterile by hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy or tubal ligation for the purpose of contraception for at least 6 weeks with appropriate documentation of such surgery
- •Postmenopausal (defined as older than 45 years of age with cessation of regular menstrual periods for 6 months and confirmed by a follicle-stimulating hormone level of > 40 mIU/mL, or amenorrhea for at least 12 months)
- •Of childbearing potential and using combined (estrogen and progestogen) or progestogen-only hormonal contraception associated with inhibition of ovulation (including oral, intravaginal, injectable, implantable, and transdermal contraceptives), or an intrauterine device (IUD), or intrauterine hormone-releasing system (IUS) for the entire duration of the study
- •Of childbearing potential and practice abstinence as a preferred and usual lifestyle, and agrees to continue practicing abstinence from Screening and for the entire duration of the study
- •Of childbearing potential, whose sole heterosexual partner has been successfully vasectomized and agrees to not have other heterosexual partners for the entire duration of the study
- •Patients meeting specific criteria for each infection site
排除标准
- •Patients who have a history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
- •Patients who need more than 3 systemic antibiotics as part of best available therapy (BAT) for the treatment of the Gram-negative infection (patients with mixed Gram-positive or anaerobic infections may receive appropriate concomitant narrow spectrum antibiotics [eg, vancomycin, linezolid, metronidazole, clindamycin])
- •Patients with coinfection caused by invasive aspergillosis, mucormycosis or other highly lethal mold
- •Patients who have central nervous system (CNS) infection (eg, meningitis, brain abscess, shunt infection)
- •Patients with infection requiring > 3 weeks of antibiotic treatment (eg, bone and joint infection, endocarditis)
- •Patients with cystic fibrosis or moderate to severe bronchiectasis
- •Patients in refractory septic shock defined as persistent hypotension despite adequate fluid resuscitation or despite vasopressive therapy at the time of Randomization
- •Patients with severe neutropenia, ie, polymorphonuclear neutrophils (PMNs) < 100 cells/μL
- •Female patients who have a positive pregnancy test at Screening or who are lactating
- •Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 30
- •Patients who have received a potentially effective antibiotic regimen for the carbapenem-resistant Gram-negative infection for a continuous duration of more than 24 hours in cUTI, or 36 hours in HAP/VAP/HCAP or BSI/sepsis during the 72 hours leading to Randomization
- •Patients with any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
- •Patients who have received another investigational drug or device within 30 days prior to study entry
- •Patients who have previously been randomized in this study or received S-649266
- •Patients receiving peritoneal dialysis
- •Patients meeting specific exclusion criteria for each infection site
研究组 & 干预措施
Cefiderocol
Experimental
Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
干预措施: Cefiderocol (Drug)
Best Available Therapy (BAT)
Active Comparator
Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
干预措施: Best Available Therapy (Drug)
结局指标
主要结局
Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis
时间窗: Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms and was defined for each diagnosis. HAP/VAP/HCAP: Clinical cure was defined as resolution or substantial improvement of Baseline signs and symptoms of pneumonia including a reduction in SOFA and CPIS scores, and improvement or lack of progression of chest radiographic abnormalities such that no antibacterial therapy was required for the treatment of the current infection. BSI/Sepsis: Clinical cure was defined as resolution or substantial improvement of Baseline signs and symptoms including a reduction in SOFA score, such that no antibacterial therapy was required for the treatment of BSI/sepsis. Participants with bacteremia must have eradication of bacteremia caused by the Gram-negative pathogen. Participants with missing data were considered as non-responders.
Percentage of Participants With Microbiologic Eradication at TOC in Participants With cUTI
时间窗: Test of cure, defined as 7 days after the end of treatment, equivalent to Study Days 14 to 21
Microbiological outcome per Baseline pathogen was determined by the sponsor as defined for each infection site. For cUTI eradication was defined as a urine culture that showed that the Gram-negative uropathogen identified at Baseline at ≥ 10⁵ colony-forming units (CFU)/mL was reduced to \< 10³ CFU/mL. Overall per-participant eradication was defined as eradication of all Baseline Gram-negative pathogens.
次要结局
- Percentage of Participants With Clinical Cure at Test of Cure in Participants With cUTI(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Sustained Clinical Cure at Follow-up By Baseline Pathogen(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Clinical Cure at End of Treatment (EOT) in Participants With HAP/VAP/HCAP or BSI/Sepsis(End of treatment, Day 7 to 14)
- Percentage of Participants With Clinical Cure at End of Treatment (EOT) in Participants With cUTI(End of treatment, Day 7 to 14)
- Percentage of Participants With Sustained Clinical Cure at Follow-up in Participants With cUTI(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Clinical Cure at End of Treatment in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(End of treatment, Day 7 to 14)
- Percentage of Participants With Microbiologic Eradication at EOT in Participants With HAP/VAP/HCAP or BSI/Sepsis(End of treatment, Day 7 to 14)
- Percentage of Participants With Microbiologic Eradication at TOC in Participants With HAP/VAP/HCAP or BSI/Sepsis(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With HAP/VAP/HCAP or BSI/Sepsis(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Sustained Clinical Cure at Follow-up (FU) in Participants With HAP/VAP/HCAP or BSI/Sepsis(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Sustained Clinical Cure at Follow-up in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Clinical Cure at Test of Cure By Baseline Pathogen(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Clinical Cure at Test of Cure in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Clinical Cure at End of Treatment By Baseline Pathogen(End of treatment, Day 7 to 14)
- Percentage of Participants With Clinical Cure at EOT By Baseline Carbapenem-resistant Pathogen(End of treatment, Day 7 to 14)
- Percentage of Participants With Sustained Clinical Cure at Follow-up By Baseline Carbapenem-resistant Pathogen(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Microbiologic Eradication at EOT in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(End of treatment, Day 7 to 14)
- Percentage of Participants With Clinical Cure at TOC By Baseline Carbapenem-resistant Pathogen(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With cUTI(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With a Composite Clinical and Microbiological Response at EOT(End of treatment, Day 7 to 14)
- All-cause Mortality at Day 14 and Day 28(Day 14 and Day 28)
- Percentage of Participants With Microbiologic Eradication at EOT in Participants With cUTI(End of treatment, Day 7 to 14)
- Percentage of Participants With Microbiologic Eradication at TOC in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Microbiologic Eradication at EOT By Baseline Pathogen(End of treatment, Day 7 to 14)
- Percentage of Participants With Microbiologic Eradication at TOC By Baseline Pathogen(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Survival Time(Days 1 to 10, 11 to 20, 21 to 30, 31 to 40, 41-50, and 51 to 60.)
- Change From Baseline in Clinical Pulmonary Infection Score (CPIS) in Participants With Pneumonia (HAP/VAP/HCAP)(Baseline, end of treatment (Day 7-14), test of cure (7 days after end of treatment, equivalent to Study Day 14 to 21) and follow-up (14 days after end of treatment, equivalent to Study Day 21 to 28))
- Number of Participants With Adverse Events(From first dose of study drug up to 28 days after last dose; maximum treatment duration was 29 days in the cefiderocol group and 22 days in the BAT group.)
- Percentage of Participants With Microbiologic Eradication at EOT By Baseline Carbapenem-resistant Pathogen(End of treatment, Day 7 to 14)
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up By Baseline Carbapenem-resistant Pathogen(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Microbiologic Eradication at TOC in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With a Composite Clinical and Microbiological Response at TOC(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Change From Baseline in Sequential Organ Failure Assessment (SOFA)(Baseline, end of treatment (Day 7 to 14), test of cure (7 days after end of treatment, equivalent to Study Day 14 to 21) and follow-up (14 days after end of treatment, equivalent to Study Day 21 to 28))
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up By Baseline Pathogen(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With Microbiologic Eradication at TOC By Baseline Carbapenem-resistant Pathogen(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants With a Composite Clinical and Microbiological Response at Follow-up(Follow-up, defined as 14 days after the end of treatment, equivalent to Study Day 21 to 28)
- Percentage of Participants Alive and With No Change in Antibiotic Treatment Due to Either Lack of Therapeutic Benefit or Drug-related Toxicity at TOC(Test of cure, defined as 7 days after end of treatment, equivalent to Study Day 14 to 21)
- Percentage of Participants With Microbiologic Eradication at EOT in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia(End of treatment, Day 7 to 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract InfectionsUrinary Tract InfectionsNCT02321800Shionogi452
已完成
2 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric ParticipantsGram-negative Bacterial InfectionsBloodstream Infections (BSI)Complicated Intra-abdominal Infection (cIAI)Hospital Acquired Pneumonia (HAP)Ventilator-acquired PneumoniaComplicated Urinary Tract Infection (cUTI)SepsisNCT04335539Shionogi54
终止
1 期
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial PneumoniaBacterial PneumoniaNCT03862040Shionogi7
已完成
2 期
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSIBloodstream InfectionsNCT03869437The University of Queensland513
终止
3 期
A Study of Ceftobiprole in Patients With Fever and Neutropenia.Pseudomonas InfectionFeverNeutropeniaGram-positive Bacterial InfectionsNCT00529282Basilea Pharmaceutica2
相关资讯
Shionogi Secures $482 Million BARDA Contract to Strengthen U.S. Biodefense Against Drug-Resistant Bacterial Threats- Shionogi Inc. received a BARDA Project BioShield contract worth up to $482 million to enhance national preparedness against drug-resistant bacterial infections and biothreat pathogens.
- The contract funds establishment of U.S. manufacturing for Fetroja (cefiderocol), procurement activities, and development for treating high-priority bioterrorism agents including melioidosis and plague.
- Fetroja represents the world's first siderophore cephalosporin antibiotic, currently approved for treating hospital-acquired pneumonia and complicated urinary tract infections caused by Gram-negative bacteria.
- The agreement includes expanding Fetroja's utility to pediatric patients with hospital-acquired pneumonia through an FDA supplemental application.5 months agoShionogi's Cefiderocol Shows 68% Clinical Cure Rate Against Highly Resistant MBL-Producing Enterobacterales in Real-World Study- The CIRCE study demonstrated that cefiderocol achieved a 68% clinical cure rate at day 14 and 83% overall survival at day 28 in 232 patients with MBL-producing Enterobacterales infections.
- MBL-producing Enterobacterales inactivate almost all beta-lactam antibiotics including carbapenems, representing critical priority pathogens with limited treatment options.
- Additional surveillance data showed sustained cefiderocol activity against Stenotrophomonas maltophilia over a 10-year period with no significant resistance development.
- The real-world evidence supports cefiderocol's effectiveness in critically ill patients, with 29% immunosuppressed and 27% in intensive care at baseline.5 months ago